ProKidney Presents Two Abstracts at ASN's Kidney Week 2025, Including Phase 2 REGEN-007 Study Results

ProKidney Corp. announced two abstracts selected for presentation at the American Society of Nephrology's Kidney Week 2025. The late-breaking poster will present Phase 2 REGEN-007 study results on renal autologous cell therapy in diabetes and CKD, while another poster will discuss the cell-specific inflammatory profile characterization of the cell therapy candidate rilparencel. Both posters will be available on the company's website after the event.

ProKidney Corp. (Nasdaq: PROK), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), has announced that it will present two posters at the upcoming American Society of Nephrology's (ASN) Kidney Week 2025 in Houston, Texas, from November 6 to 9, 2025. The presentations will highlight recent advancements in the company's cell therapy platform, specifically in the treatment of CKD.

One of the presentations, a late-breaking poster, will report the Phase 2 REGEN-007 study results on "Renal Autologous Cell Therapy in Diabetes and CKD." This poster will be presented on November 6, 2025, from 10:00 AM to 12:00 PM CST, at Board #TH-PO1203, according to a Stocktitan announcement. The study aims to evaluate the efficacy of autologous cell therapy in preserving kidney function for patients with diabetes and CKD.

The second poster, titled "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," will also be presented on November 6, 2025, from 10:00 AM to 12:00 PM CST, at Board #TH-PO0575, as noted in the Stocktitan announcement. This poster will discuss the inflammatory profile of the cell therapy candidate rilparencel, providing insights into its potential therapeutic effects and safety profile.

Both posters will be available on ProKidney's website after the event, providing further details and findings from the research presented at ASN Kidney Week 2025.

ProKidney's lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation. It is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes, according to a MarketScreener filing.

The company's focus on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient's own cells isolated for treatment positions ProKidney as a pioneer in the field. The company's REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant's own kidney tissue, as noted in the MarketScreener filing.